UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Harnessing the Immune System for the Treatment of Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2013-03, Vol.31 (8), p.1021-1028

Brahmer, Julie R

2013

Volltextzugriff (PDF)

Cancer immunotherapy: a future paradigm shift in the treatment of non-small cell lung cancer

Clinical cancer research, 2015-03, Vol.21 (5), p.976-984

2015

Volltextzugriff (PDF)

Managing Resistance to Immune Checkpoint Inhibitors in Lung Cancer: Treatment and Novel Strategies

Journal of clinical oncology, 2022-02, Vol.40 (6), p.598-610

2022

Volltextzugriff (PDF)

Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer

The New England journal of medicine, 2019-11, Vol.381 (21), p.2020-2031

2019

Volltextzugriff (PDF)

The emerging role of epigenetic therapeutics in immuno-oncology

Nature reviews. Clinical oncology, 2020-02, Vol.17 (2), p.75-90

2020

Volltextzugriff (PDF)

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

The New England journal of medicine, 2016-11, Vol.375 (19), p.1823-1833

2016

Volltextzugriff (PDF)

Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer

Nature reviews. Clinical oncology, 2014-01, Vol.11 (1), p.24-37

2014

Volltextzugriff (PDF)

Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater

Journal of clinical oncology, 2019-03, Vol.37 (7), p.537-546

2019

Volltextzugriff (PDF)

Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer

Nature medicine, 2018-05, Vol.24 (5), p.638-646

2018

Volltextzugriff (PDF)

Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50

Journal of clinical oncology, 2021-07, Vol.39 (21), p.2339-2349

2021

Volltextzugriff (PDF)

Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer

The New England journal of medicine, 2022-05, Vol.386 (21), p.1973-1985

2022

Volltextzugriff (PDF)

Immune Checkpoint Blockade: The Hope for Immunotherapy as a Treatment of Lung Cancer?

Seminars in oncology, 2014-02, Vol.41 (1), p.126-132

Brahmer, Julie R

2014

Volltextzugriff (PDF)

Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update

Journal of clinical oncology, 2015-10, Vol.33 (30), p.3488-3515

2015

Volltextzugriff (PDF)

Immune checkpoint modulation for non-small cell lung cancer

Clinical cancer research, 2015-05, Vol.21 (10), p.2256-2262

2015

Volltextzugriff (PDF)

Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab

Annals of the rheumatic diseases, 2017-01, Vol.76 (1), p.43-50

2017

Volltextzugriff (PDF)

Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation

Annals of the rheumatic diseases, 2020-03, Vol.79 (3), p.332-338

2020

Volltextzugriff (PDF)

Pneumonitis in Non–Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors

Journal of thoracic oncology, 2018-12, Vol.13 (12), p.1930-1939

2018

Volltextzugriff (PDF)

Pivotal PD-1 Treatment Helps Change Standard of Care in Lung Cancer

Oncology (Williston Park, N.Y.), 2021-12

Brahmer, Julie R

2021

Volltextzugriff (PDF)

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events

Journal for immunotherapy of cancer, 2021-06, Vol.9 (6), p.e002435

2021

Volltextzugriff (PDF)

Nivolumab: targeting PD-1 to bolster antitumor immunity

Future oncology (London, England), 2015-05, Vol.11 (9), p.1307-1326

2015

Volltextzugriff (PDF)

Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study

Journal of clinical oncology, 2018-06, Vol.36 (17), p.1675-1684

2018

Volltextzugriff (PDF)

Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy

Clinical cancer research, 2014-10, Vol.20 (19), p.5064-5074

2014

Volltextzugriff (PDF)

Immune-related adverse events of checkpoint inhibitors

Nature reviews. Disease primers, 2020-05, Vol.6 (1), p.38-38, Article 38

2020

Volltextzugriff (PDF)

Immune checkpoint inhibitors: making immunotherapy a reality for the treatment of lung cancer

Cancer immunology research, 2013-08, Vol.1 (2), p.85-91

2013

Volltextzugriff (PDF)

1 – 25 von 436

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(407)
Mit Volltextzugriff
(373)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(217)
Life Sciences & Biomedicine
(212)
Humans
(191)
Oncology
(181)
Lung Neoplasms - Drug Therapy
(101)
Female
(100)
Male
(96)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(95)
Aged
(86)
Immunotherapy
(85)
Middle Aged
(81)
Lung Cancer
(76)
Adult
(67)
Tumors
(59)
Lung Neoplasms - Pathology
(57)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(48)
Carcinoma, Non-Small-Cell Lung - Pathology
(46)
Chemotherapy
(46)
Aged, 80 And Over
(41)
Cancer
(40)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(3)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Harnessing the Immune System for the Treatment of Non–Small-Cell Lung Cancer

Cancer immunotherapy: a future paradigm shift in the treatment of non-small cell lung cancer

Managing Resistance to Immune Checkpoint Inhibitors in Lung Cancer: Treatment and Novel Strategies

Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study

Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer

The emerging role of epigenetic therapeutics in immuno-oncology

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer

Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater

Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer

Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50

Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer

Immune Checkpoint Blockade: The Hope for Immunotherapy as a Treatment of Lung Cancer?

Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update

Immune checkpoint modulation for non-small cell lung cancer

Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab

Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation

Pneumonitis in Non–Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors

Pivotal PD-1 Treatment Helps Change Standard of Care in Lung Cancer

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events

Nivolumab: targeting PD-1 to bolster antitumor immunity

Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study

Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy

Immune-related adverse events of checkpoint inhibitors

Immune checkpoint inhibitors: making immunotherapy a reality for the treatment of lung cancer

Suchergebnisse filtern